Amedisys, Inc. (NASDAQ:AMED) Shares Sold by ClearAlpha Technologies LP

ClearAlpha Technologies LP lowered its position in Amedisys, Inc. (NASDAQ:AMED) by 23.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,653 shares of the health services provider’s stock after selling 18,208 shares during the quarter. Amedisys accounts for approximately 3.7% of ClearAlpha Technologies LP’s holdings, making the stock its 8th biggest holding. ClearAlpha Technologies LP owned about 0.18% of Amedisys worth $5,416,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in shares of Amedisys during the 4th quarter valued at approximately $83,061,000. Wealthfront Advisers LLC bought a new position in Amedisys during the 4th quarter valued at $72,970,000. Pacer Advisors Inc. grew its holdings in Amedisys by 11,621.9% during the 4th quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider’s stock worth $50,679,000 after acquiring an additional 553,435 shares in the last quarter. Birnam Oak Advisors LP bought a new stake in shares of Amedisys in the 4th quarter worth about $15,832,000. Finally, First Trust Advisors LP bought a new stake in shares of Amedisys in the 4th quarter worth about $9,059,000. Institutional investors and hedge funds own 94.36% of the company’s stock.

Amedisys Stock Performance

Shares of AMED stock opened at $91.76 on Monday. The company has a market cap of $3.01 billion, a P/E ratio of 36.41, a PEG ratio of 1.78 and a beta of 0.89. The business has a 50 day moving average of $92.14 and a two-hundred day moving average of $91.86. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.05 by ($0.09). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The company had revenue of $598.05 million during the quarter, compared to the consensus estimate of $602.38 million. As a group, analysts anticipate that Amedisys, Inc. will post 4.4 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on AMED shares. Stephens reiterated an “equal weight” rating and issued a $101.00 price target on shares of Amedisys in a research note on Tuesday, March 4th. Royal Bank of Canada reiterated an “outperform” rating and issued a $100.00 target price on shares of Amedisys in a research report on Wednesday, April 16th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Amedisys currently has a consensus rating of “Hold” and an average target price of $100.75.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.